Latest News

Investigators report no grade 4 adverse effects among patients who received elacestrant/abemaciclib in the phase 1b/2 ELECTRA trial.
Elacestrant Combo Shows Activity, Tolerability in Metastatic Breast Cancer

October 6th 2024

Investigators report no grade 4 adverse effects among patients who received elacestrant/abemaciclib in the phase 1b/2 ELECTRA trial.

Concurrent chemoradiation yielded similar contralateral breast recurrence outcomes vs a sequential approach in early-stage breast cancer.
Adjuvant cCRT Improves Disease Control, But Increases AEs in Breast Cancer

October 3rd 2024

Use of DCISionRT may open new options for tailored treatments among patients with HER2-positive ductal carcinoma in situ.
Biosignature Test May Predict Residual Risk Post-BCS/RT in HER2+ DCIS

October 2nd 2024

Data from DESTINY-Breast06 support the priority review designation for T-DXd as a treatment for HER2-low or HER2-ultralow breast cancer.
T-DXd Earns FDA Priority Review in Pretreated HER2-Low Breast Cancer

October 1st 2024

Hypofractionated RT After Mastectomy Is Noninferior to SOC in Breast Cancer
Hypofractionated RT After Mastectomy Is Noninferior to SOC in Breast Cancer

September 30th 2024